Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)

被引:104
作者
Yu, Roger J. [1 ]
Krantz, Matthew S. [2 ]
Phillips, Elizabeth J. [1 ]
Stone, Cosby A., Jr. [2 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
FDA; FAERS; Anaphylaxis; Drug allergy; Death; Fatal;
D O I
10.1016/j.jaip.2020.09.021
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
BACKGROUND: Drug-induced anaphylaxis is a well-known adverse drug reaction for some drug classes, but emerging drug causes of anaphylaxis and novel mechanisms may contribute in unrecognized ways. OBJECTIVE: We sought to determine the top drugs reported in association with anaphylaxis and anaphylaxis followed by death in the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We reviewed the publicly available FAERS database from 1999 to 2019. Using search terms "anaphylactic shock" or "anaphylactic reaction" and sorting cases by generic drug names, we counted and trended reports to FAERS in which a drug was associated with anaphylaxis or anaphylaxis followed by death. RESULTS: From 1999 to 2019, there were 17,506,002 adverse drug events reported in FAERS, of which 47,496 (0.27%) were reported as anaphylaxis. Excluding patients without age, sex, or country data, respectively, the median age of patients in reports of anaphylaxis was 52 (interquartile range: 28), 62.71% were female, and 13,899 of 34,381 (40.43%) reports were from the United States. There were 2984 of 47,496 (6.28%) reports of anaphylaxis followed by death. Top drug classes associated with anaphylaxis in FAERS were antibiotics, monoclonal antibodies (mAbs), nonsteroidal anti-inflammatory drugs, and acetaminophen. Top drug classes associated with anaphylaxis deaths were antibiotics, radiocontrast agents, and intraoperative agents. Linear regression demonstrated reports of anaphylaxis to mAbs increasing at an average rate of 0.77% of total anaphylaxis reports per year (95% confidence interval: 0.65, 0.88) from 2.00% in 1999 to 17.37% in 2019, faster than any other drug class. CONCLUSION: Antibiotics were highly reported for anaphylaxis overall and anaphylaxis followed by death. Increasing reports were noted for anaphylaxis to mAb therapies. (C) 2020 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:819 / +
页数:13
相关论文
共 37 条
  • [1] Improving the Effectiveness of Penicillin Allergy De-labeling
    Bourke, Jack
    Pavlos, Rebecca
    James, Ian
    Phillips, Elizabeth
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (03) : 365 - +
  • [2] First-dose anaphylaxis to infliximab: a case of mammalian meat allergy
    Chitnavis, Maithili
    Stein, Daniel J.
    Commins, Scott
    Schuyler, Alex J.
    Behm, Brian
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2017, 5 (05) : 1425 - 1426
  • [3] Cho H, 2019, MEDICINE, V98, DOI [10.1097/md.0000000000014114, 10.1097/MD.0000000000014114]
  • [4] Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
    Chung, Christine H.
    Mirakhur, Beloo
    Chan, Emily
    Le, Quynh-Thu
    Berlin, Jordan
    Morse, Michael
    Murphy, Barbara A.
    Satinover, Shama M.
    Hosen, Jacob
    Mauro, David
    Slebos, Robbert J.
    Zhou, Qinwei
    Gold, Diane
    Hatley, Tina
    Hicklin, Daniel J.
    Platts-Mills, Thomas A. E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) : 1109 - 1117
  • [5] Drug-Induced Anaphylaxis Documented in Electronic Health Records
    Dhopeshwarkar, Neil
    Sheikh, Aziz
    Doan, Raymond
    Topaz, Maxim
    Bates, David W.
    Blumenthal, Kimberly G.
    Zhou, Li
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (01) : 103 - 111
  • [6] Off-Label Uses of Omalizumab
    El-Qutob, David
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2016, 50 (01) : 84 - 96
  • [7] Investigation of pegloticase-associated adverse events from a nationwide reporting system database
    Gentry, William
    Dotson, Michael
    Williams, Brian
    Hartley, Melissa
    Stafford, Kristen
    Bottorff, Michael
    Gandhi, Pranav
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (09) : 722 - 727
  • [8] Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
    Iarikov D.
    Wassel R.
    Farley J.
    Nambiar S.
    [J]. Infectious Diseases and Therapy, 2015, 4 (4) : 433 - 458
  • [9] Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations
    Jerschow, Elina
    Lin, Robert Y.
    Scaperotti, Moira M.
    McGinn, Aileen P.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (06) : 1318 - +
  • [10] Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
    Kadoyama, Kaori
    Kuwahara, Akiko
    Yamamori, Motohiro
    Brown, J. B.
    Sakaeda, Toshiyuki
    Okuno, Yasushi
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2011, 30